Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation. (24th May 2017)

• Record Type: Journal Article
• Authors: Nishimoto, Mitsutaka; Koh, Hideo; Tokuwame, Atsushi; Makuuchi, Yosuke; Kuno, Masatomo; Takakuwa, Teruhito; Okamura, Hiroshi; Koh, Shiro; Yoshimura, Takuro; Nanno, Satoru; Nakamae, Mika; Hirose, Asao; Nakashima, Yasuhiro; Nakane, Takahiko; Hino, Masayuki; Nakamae, Hirohisa
• Is Part Of: British journal of clinical pharmacology. Volume 83:Number 9(2017)
• Page Start: 2000
• Page End: 2007
• Publication Date: 2017-05-24
• Subjects: allogeneic haematopoietic cell transplantation -- caspofungin -- drug interaction; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.13303
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aim: Small‐scale clinical studies have reported on drug interactions between caspofungin (CPFG) and calcineurin inhibitors in healthy subjects; however, little is known about these interactions in allogeneic haematopoietic cell transplantation (allo‐HCT) patients. Methods: We retrospectively assessed the drug interactions and safety profiles in allo‐HCT recipients treated concomitantly with CPFG and calcineurin inhibitors. Results: Ninety‐one consecutive cases were evaluated. There were no statistically significant differences in the plasma concentration/dose (C/D) ratios of tacrolimus (TAC) in 34 patients before and after co‐administration with CPFG (median: 575.6–672.4, P = 0.200). In contrast, the median C/D ratio of cyclosporin A (CsA) in 16 patients was significantly elevated after co‐administration with CPFG (median: 62.8–74.9, P = 0.016). There were no serious adverse effects on liver or renal function associated with the therapy. Conclusions: Our data show that CPFG did not affect the pharmacokinetics of TAC and that it could mildly increase CsA blood concentrations in allo‐HCT patients.